{
    "1665327538757935105": {
        "author_id": "5383942",
        "created_at": "2023-06-04T12:00:00.000Z",
        "edit_history_tweet_ids": [
            "1665327538757935105"
        ],
        "entities": {
            "annotations": [
                {
                    "end": 31,
                    "normalized_text": "myelofibrosis",
                    "probability": 0.8196,
                    "start": 19,
                    "type": "Other"
                },
                {
                    "end": 69,
                    "normalized_text": "BloodCancer",
                    "probability": 0.7207,
                    "start": 59,
                    "type": "Other"
                },
                {
                    "end": 225,
                    "normalized_text": "ASCO23",
                    "probability": 0.6184,
                    "start": 220,
                    "type": "Other"
                }
            ],
            "hashtags": [
                {
                    "end": 70,
                    "start": 58,
                    "tag": "BloodCancer"
                },
                {
                    "end": 226,
                    "start": 219,
                    "tag": "ASCO23"
                }
            ]
        },
        "id": "1665327538757935105",
        "lang": "en",
        "public_metrics": {
            "bookmark_count": 1,
            "impression_count": 3166,
            "like_count": 9,
            "quote_count": 0,
            "reply_count": 1,
            "retweet_count": 1
        },
        "text": "People living with myelofibrosis (MF), a rare and complex #BloodCancer, face unique challenges as they navigate symptoms and treatment paths. \n\nLearn how we aim to address these challenges through our ongoing research. #ASCO23"
    }
}